PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
20.86%
Positive revenue growth while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch might see a relative strength advantage in a tough sector.
30.04%
Positive gross profit growth while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch would see a notable competitive edge in cost or pricing.
-72.06%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is -191.68%. Seth Klarman would check if external or internal factors caused the decline.
-130.61%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is -179.71%. Seth Klarman would check if structural or cyclical issues are at play.
-61.23%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is -206.97%. Seth Klarman would investigate factors dragging net income down.
100.00%
Positive EPS growth while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch might see a strong advantage in per-share earnings compared to peers.
100.00%
Positive diluted EPS growth while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch might see a real advantage in how this firm manages share count or drives net income.
-100.00%
Share reduction while Drug Manufacturers - Specialty & Generic median is 3.06%. Seth Klarman would see a relative advantage if others are diluting.
-100.00%
Diluted share reduction while Drug Manufacturers - Specialty & Generic median is 3.06%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
-122.31%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-232.20%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
-100.00%
Negative 10Y revenue/share CAGR while Drug Manufacturers - Specialty & Generic median is -15.78%. Seth Klarman would see if the entire sector or just this company faces long-term decline.
-100.00%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is -5.58%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
-100.00%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is -4.60%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
100.00%
OCF/share CAGR of 100.00% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
100.00%
OCF/share CAGR of 100.00% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
100.00%
3Y OCF/share growth of 100.00% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
100.00%
Positive 10Y net income/share CAGR while Drug Manufacturers - Specialty & Generic is negative. Peter Lynch sees a resilient enterprise vs. struggling peers.
100.00%
Positive 5Y CAGR while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch sees a notable advantage vs. peers struggling to grow net income/share.
100.00%
Positive 3Y CAGR while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch sees a big short-term advantage vs. peers struggling with profit declines.
-100.00%
Negative 10Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 110.11%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-100.00%
Negative 5Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 18.46%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-100.00%
Negative 3Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 7.36%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
17.53%
Slight AR growth while Drug Manufacturers - Specialty & Generic cuts AR. Peter Lynch wonders if the firm is missing an opportunity to collect faster or if peers face sales declines.
2.84%
Inventory reduction well below Drug Manufacturers - Specialty & Generic median. Joel Greenblatt might see a sign of superior operational or supply-chain efficiency.
-39.05%
Assets shrink while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-100.00%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is -4.60%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-4.41%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
-60.00%
R&D dropping while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
12.05%
SG&A growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.